KPV Benefits: Claims vs What Studies Show
Benefits people claim for KPV, set against what published studies measured, and where no study exists.
- Strongest evidence
- Animal
- Human / animal studies
- 0 / 4
- in our evidence file (PubMed search, 11 Oct 2026)
- FDA status
- Not approved
- Off Category 2, 15 Apr 2026
Claimed benefits and what studies show
Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Claim | Best evidence | Studies (human / animal) | What was measured | Page |
|---|---|---|---|---|
| Inflammation | Animal evidence, 2 of 4 | 0 / 6 | DSS colitis recovery; Survival in MC1R-nonfunctional mice; Colitis incidence (oral KPV) | Evidence for inflammation |
| Gut health | Animal evidence, 2 of 4 | 0 / 2 | DSS colitis recovery; Survival in MC1R-nonfunctional mice; Colitis incidence (oral KPV) | Evidence for gut health |
| Skin | In vitro evidence, 1 of 4 | 0 / 3 | Keratinocyte viability and IL-1beta; Skin permeation; Cyclic AMP signalling | Evidence for skin |
| Allergies | In vitro evidence, 1 of 4 | 0 / 1 | Airway epithelial inflammatory signalling | Evidence for allergies |
Strongest study per claim: Inflammation, Inflammatory bowel diseases 2008, PMID 18092346; Gut health, Inflammatory bowel diseases 2008, PMID 18092346; Skin, Tissue & cell 2025, PMID 40073467.
What the studies measured
| Outcome | Result | Study type | Source |
|---|---|---|---|
| DSS colitis recovery | KPV-treated mice recovered earlier and regained more body weight in DSS colitis. | Animal · mouse (not a human result) | Inflammatory bowel diseases 2008, PMID 18092346 |
| Survival in MC1R-nonfunctional mice | KPV treatment rescued all treated MC1R-nonfunctional mice from death during DSS colitis. | Animal · mouse (not a human result) | Inflammatory bowel diseases 2008, PMID 18092346 |
| Colitis incidence (oral KPV) | Oral KPV in drinking water reduced the incidence of DSS- and TNBS-induced colitis in mice and lowered inflammatory cytokine expression. | Animal · mouse (plus human intestinal epithelial and T cell lines) (not a human result) | Gastroenterology 2008, PMID 18061177 |
| Peritonitis (neutrophil accumulation) | KPV reduced inflammatory cell accumulation in mouse peritonitis through a mechanism distinct from other melanocortin peptides. | Animal · mouse (not a human result) | The Journal of pharmacology and experimental therapeutics 2003, PMID 12750433 |
| Fever | The tripeptide reduced fever in rabbits after central (0.5-2.0 mg) and peripheral (2-200 mg) administration. | Animal · rabbit (not a human result) | Peptides 1984, PMID 6333677 |
| Keratinocyte viability and IL-1beta | KPV at 50 ug/mL restored cell viability and reduced IL-1beta secretion in PM10-exposed keratinocytes. | In vitro (not a human result) | Tissue & cell 2025, PMID 40073467 |
| Skin permeation | KPV did not permeate human skin by passive diffusion alone (below the detection limit of 0.01 ug/mL); microneedles and iontophoresis were needed. | In vitro (not a human result) | Journal of pharmaceutical sciences 2017, PMID 28343991 |
| Degradation under stress | Under acid, alkali and hydrogen peroxide stress KPV degraded mainly to lys-pro-diketopiperazine. | In vitro (not a human result) | Biomedical chromatography 2015, PMID 25298219 |
| Airway epithelial inflammatory signalling | KPV dose-dependently inhibited NF-kB signalling, MMP-9 activity, and IL8 and eotaxin secretion in cultured airway cells. | In vitro (not a human result) | International journal of physiology, pathophysiology and pharmacology 2012, PMID 22837805 |
| Cyclic AMP signalling | KPV did not raise cyclic AMP in human keratinocytes (mechanism study; no clinical outcome). | In vitro (not a human result) | The Journal of investigative dermatology 2004, PMID 15102092 |
What KPV is, from the studies
KPV is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone.[6]
The gut-health claim: mouse colitis studies
In mice with DSS colitis, KPV led to earlier recovery and significantly stronger regain of body weight (animal study).[1]
In melanocortin-1-receptor-deficient mice, KPV rescued every treated animal from death during DSS colitis (animal study).[1]
Oral KPV in drinking water reduced the incidence of DSS- and TNBS-induced colitis in mice (animal study).[2]
Inflammation, skin and allergy claims: cells and animals only
In mice with crystal-induced peritonitis, systemic KPV significantly reduced the build-up of polymorphonuclear leukocytes in the peritoneal cavity (animal study).[3]
In human HaCaT skin cells exposed to fine dust, KPV restored cell viability and reduced IL-1β secretion (cell study).[5]
In immortalised human bronchial epithelial cells, KPV inhibited NFκB, IL8 and eotaxin secretion in a dose-dependent way, which is the nearest the cached sources come to an allergy-type claim (cell study).[8]
In rabbits made febrile, the KPV tripeptide reduced fever after both central and peripheral administration (animal study).[4]
Claims with no human study
None of the 9 cached KPV abstracts reports a study in living human participants; they are mouse, rabbit, cell-line and ex vivo skin studies, so every benefit above is unconfirmed in people.
Calculated from cached abstracts 18092346, 18061177, 12750433, 22837805, 40073467, 15102092, 6333677, 28343991, 25298219; human participant studies 0; animal only yes. Formula: count of cached abstracts reporting living human participants = 0
A dated PubMed search (2026-10-02) for KPV with clinical-trial terms returned 9 records; none of the cached abstracts behind this page is a KPV trial in people.
Calculated from evidence file web/src/data/evidence/kpv.json; query (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (clinical trial[pt] OR randomized[tiab] OR patients[tiab]); date 2026-10-02; count 9. Formula: count of PubMed records returned by the dated query
More on KPV
Common questions
Is KPV proven to work?
The strongest study we summarise for KPV is animal evidence, among 9 studies. That is not proof it works in people.
What does KPV peptide do?
The cached studies describe an anti-inflammatory tripeptide: in mice it reduced colitis, and the authors of a mouse peritonitis study conclude it acts differently from the core MSH peptides.[3]
Is KPV peptide proven for gut health?
No. The gut evidence is from mouse colitis models, with no human trial in the cached set.
Calculated from mouse colitis studies 2; human trials 0. Formula: cached gut studies in people = 0
More on KPV
Sources
- 1Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.Inflammatory bowel diseases · 2008PMID 18092346Accessed 2 Oct 2026
- 2PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.Gastroenterology · 2008PMID 18061177Accessed 2 Oct 2026
- 3Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides.The Journal of pharmacology and experimental therapeutics · 2003PMID 12750433Accessed 2 Oct 2026
- 4Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit.Peptides · 1984PMID 6333677Accessed 2 Oct 2026
- 5Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway.Tissue & cell · 2025PMID 40073467Accessed 2 Oct 2026
- 6Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin.Journal of pharmaceutical sciences · 2017PMID 28343991Accessed 2 Oct 2026
- 7Stability-indicating HPLC assay for lysine-proline-valine (KPV) in aqueous solutions and skin homogenates.Biomedical chromatography : BMC · 2015PMID 25298219Accessed 2 Oct 2026
- 8Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists.International journal of physiology, pathophysiology and pharmacology · 2012PMID 22837805Accessed 2 Oct 2026
- 9alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells.The Journal of investigative dermatology · 2004PMID 15102092Accessed 2 Oct 2026
- 10PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) (132 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (alpha-MSH[tiab] OR melanocortin[tiab] OR colitis[tiab] OR inflammat*[tiab]) (95 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (clinical trial[pt] OR randomized[tiab] OR patients[tiab]) (9 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
Found an error? Report a correction.